

Funded Clinical Trial for Dogs with Spontaneous Tumors

A new clinical trial option is now available for dogs with measurable malignant tumors with special interest in squamous cell carcinoma and sarcomas.

Trial Summary

A minimum of 13 dogs with spontaneous tumors will be treated with spores of a modified anaerobic bacteria. Treated dogs will be monitored closely after treatment with follow-up required 3, 5, 8 and 15 days post treatment. While the patient remains on study, there will also be rechecks after 1 month, 3 months, 6 months, 9 months, 12 months, and 24 months from the initial treatment.

Trial Support and Funding

Study drug, diagnostic tests, and follow-up exams will be paid for by the study sponsor. In the event that side effects are attributed to the study drug, the study will pay for medical management of the side effects.

Trial Eligibility

Inclusion Criteria Includes:

- Client-owned dogs with spontaneous tumors with a preference for squamous cell carcinoma and sarcomas
- Histologic or cytologic confirmation of tumor diagnosis
- Dogs that have failed standard therapy or whose owners have declined such therapy
- At least one palpable lesion measuring ≥ 1 cm in diameter
- Weight ≥ 10 kg
- Dogs able to function normally (Modified ECOG Performance Score of 0 or 1)

Exclusion Criteria Includes:

- Evidence of an active bacterial infection based on physical examination and/or complete blood count evaluation
- Received antibiotic therapy within 7 days prior to spore infusion for a confirmed or suspected infection
- Cancer therapy of any type (chemotherapy, radiation therapy, immunotherapy, etc.) within 3 weeks of study treatment
- Tumors located in areas where abscess development would be catastrophic, such as nasal tumors that extend into the brain or significant pulmonary metastatic disease